Hubert Piessevaux

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Pedro Pimentel‐Nunes, Mário Dinis‐Ribeiro, Thierry Ponchon et al. · Endoscopy · 2015 · 1.3K citations · Full text

Medicine, Oncology, Surgery +15

Role of impaired gastric accommodation to a meal in functional dyspepsia

Jan Tack, Hubert Piessevaux, Bernard Coulie et al. · Gastroenterology · 1998 · 1.1K citations · Full text

Medicine, Physiology, Gastroenterology +10

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Wendy De Roock, Hubert Piessevaux, Joris De Schutter et al. · Annals of Oncology · 2007 · 827 citations · Full text

Medicine, Oncology, Radiology +12

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 747 citations

Medicine, Oncology, Pharmacology +17